Prestige Biopharma appoints Nexia Samduk as external auditor

• Prestige Biopharma appointed Nexia Samduk as external auditor, replacing its prior auditor.
• Audit contract runs from July 1, 2026 to June 30, 2027.
• Filing dated Sept. 29, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prestige Biopharma Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20260929800653), on September 29, 2026, and is solely responsible for the information contained therein.